The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Here's why the Vanguard Utilities ETF (NYSEMKT: VPU), Vanguard Consumer Staples ETF (NYSEMKT: VDC), and Vanguard Health Care ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Markets are also analyzed by application. One of Europe's most significant strategic assets is the life science industry, which produces cutting-edge drugs and vaccines essential to the long-term ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Yesterday, US health officials proposed getting rid of oral drugs containing the decongestant phenylephrine over concerns ...